Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | GALR3 | O60755 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | STAT3 | P40763 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14476963 | 0.87 | BCHE (0.61) | TSHRRAB9ASMN1; SMN2NAMPTMEN1 | |
| SCHEMBL306349 | 0.84 | BCHE (0.56) | RAB9ASMN1; SMN2MEN1KMT2ABCHE | |
| SCHEMBL679125 | 0.83 | TSHR (0.69) | TSHRPKMSMN1; SMN2GAAHSD17B10 | |
| SCHEMBL8142603 | 0.83 | TSHR (0.73) | TSHRPKMMEN1KMT2AGAA | |
| SCHEMBL25528963 | 0.81 | LMNA (0.58) | TSHRPKMRAB9ASMN1; SMN2KMT2A | |
| Hydrochloric Acid SCHEMBL7130171 | 0.81 | TSHR (0.67) | TSHRPKMRAB9ASMN1; SMN2GAA | |
| SCHEMBL3836378 | 0.81 | BCHE (0.64) | TSHRPKMRAB9ASMN1; SMN2NAMPT | |
| SCHEMBL11429211 | 0.80 | TSHR (0.69) | TSHRPKMRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL9863064 | 0.80 | TSHR (0.69) | TSHRPKMRAB9AMEN1KMT2A | |
| SCHEMBL16477197 | 0.80 | TSHR (0.69) | TSHRPKMRAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151003-A1 | COMPOUNDS AND METHODS OF USE | EXELIXIS INC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230151003-A1 | COMPOUNDS AND METHODS OF USE | EXELIXIS INC (US) | 2023-05-18 | — | — | US | disclosed |
| CN-115605478-A | Compounds and methods of use | 埃克塞里艾克西斯公司（US） | 2023-01-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151003-A1 | COMPOUNDS AND METHODS OF USE | PRKACB, PRKACA, PRKX | TSHR 2982/4885PKM 345/4885RAB9A 2620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.